论文部分内容阅读
目的：评估纳洛酮治疗肝硬化工临床型肝性脑病（ＳＨＥ）的疗效。方法：４７例ＳＨＥ随机分为治疗组２４例（Ａ组），对照组２３例（Ｂ组）。双盲法分别给予治疗组纳洛酮０．４ ｍｇ（１ｍＬ）、对照组０．９％氯化钠１ｍＬ，均１日 １次肌肉注射，连用 １０日。用药前后分别行数字连接试验（ＮＣＴ）、数字符号试验（ＤＳ）检测及测定血氨，并随访有否发生临床型肝性脑病。结果：治疗组治疗后 ＮＣＴ、 ＤＳ均比治疗前明显改善，Ｐ＜０．０１，且无１例发展为临床型肝性脑病。不良反应轻微。对照组治疗前后ＮＣＴ、ＯＳ无变化，发生临床型肝性脑病３例。结论：纳洛酮是一种有效、安全的ＳＨＥ治疗药物，值得临床推广试用。
Objective: To evaluate the efficacy of naloxone in the treatment of clinical hepatic encephalopathy (SHE) in cirrhosis. Methods: Forty-seven SHE were randomly divided into treatment group (24 cases) and control group (23 cases). Double-blind method were given to the treatment group naloxone 0.4 mg (1 mL), the control group 0.9% sodium chloride 1 mL, were intramuscularly on the 1st, once every 10 days. Before and after treatment, digital connection test (NCT), digital sign test (DS) were used to detect and measure blood ammonia, and whether clinical hepatic encephalopathy was followed up. Results: After treatment, the NCT and DS of the treatment group were significantly improved than those before treatment, P <0.01, and none of them developed clinical hepatic encephalopathy. Minor adverse reactions. The control group before and after treatment NCT, OS no change, the occurrence of clinical hepatic encephalopathy in 3 cases. Conclusion: Naloxone is an effective and safe drug for SHE and worthy of clinical trial.